TP53 and neoplasm: ATRA, which we used as a gap junction enhancer, is known to inhibit the growth of tumor cells, leading to differentiation, apoptosis and anti-tumor gene expression (e.g., p53, Foxo1, Foxo3, and p21) [46,47].